Vyleesi and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

How Bremelanotide Affects Drug Transporters

Bremelanotide is a synthetic cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Its pharmacokinetic profile differs substantially from small-molecule drugs, and its transporter interactions drive the most clinically significant drug-drug interactions on its label.

OATP1B1 and OATP1B3 Inhibition

The organic anion-transporting polypeptides OATP1B1 (gene: SLCO1B1) and OATP1B3 (gene: SLCO1B3) are expressed on the sinusoidal membrane of hepatocytes [2]. Their primary job is extracting drugs from portal blood into liver cells, where further metabolism and biliary excretion occur. When a drug blocks these transporters, its substrates accumulate in systemic circulation.

In vitro studies summarized in the FDA-approved bremelanotide prescribing information confirm that bremelanotide inhibits both OATP1B1 and OATP1B3 [1]. The clinical pharmacology section explicitly states: "Bremelanotide is an inhibitor of OATP1B1, OATP1B3, and OCT1 transporters." Clinicians should treat this not as a theoretical signal but as a confirmed finding that informed the FDA's labeling decision.

CYP450 and P-gp Involvement

Bremelanotide is not a meaningful inhibitor or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations, per its prescribing information [1]. It is also not a P-glycoprotein (P-gp) substrate or inhibitor of note. This means the rosuvastatin interaction is almost entirely transporter-mediated rather than CYP-driven, a distinction that matters for choosing alternative management strategies.

Why Rosuvastatin Is Particularly Vulnerable

Rosuvastatin (Crestor and generics) is a hydrophilic HMG-CoA reductase inhibitor approved for hyperlipidemia, mixed dyslipidemia, and primary prevention of cardiovascular events [3]. Its hydrophilicity means it does not passively diffuse into hepatocytes. Instead, it depends heavily on active uptake via OATP1B1 and OATP1B3 to reach its site of action in the liver [2].

Transporter Dependence and Myopathy Risk

Because rosuvastatin relies on OATP1B1/1B3 for hepatic entry, anything that inhibits these transporters simultaneously reduces hepatic extraction and raises systemic (muscle-level) exposure. This is the same mechanistic pathway responsible for the rosuvastatin-cyclosporine interaction, which led the FDA to cap the rosuvastatin dose at 5 mg/day in transplant patients on cyclosporine [3].

The International Transporter Consortium has published framework guidance on OATP1B1/1B3 substrates and their associated myopathy risk [2]. Rosuvastatin, pravastatin, pitavastatin, and atorvastatin all qualify as OATP1B1 substrates, though their relative dependence differs. Rosuvastatin sits among the highest in transporter dependence for hepatic uptake, making it especially susceptible when OATP function is impaired.

Pharmacogenomic Context

The SLCO1B1 c.521T>C (rs4149056) variant independently reduces OATP1B1 function. Carriers of the CC genotype have up to five-fold higher rosuvastatin exposure compared with TT homozygotes [4]. Adding an OATP inhibitor such as bremelanotide on top of a reduced-function genotype could compound systemic statin exposure further. The Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for statins and SLCO1B1 recommends prescribers consider genotype-guided statin selection [4]. Patients who are already intermediate or poor OATP1B1 metabolizers face a higher-magnitude interaction.

Clinical Significance and FDA Labeling

The FDA prescribing information for bremelanotide contains a direct contraindication-adjacent warning: "Avoid use with drugs that are substrates of OATP1B1 or OATP1B3 (e.g., rosuvastatin)" [1]. This language does not carry the weight of a formal contraindication, but it signals that the agency reviewed the interaction data and judged avoidance as the appropriate default recommendation.

Severity Classification

Most clinical DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) classify this interaction as moderate to major. The DDI classification depends on:

• Magnitude of OATP inhibition (Ki values for bremelanotide vs. OATP1B1/1B3 substrates)
• Rosuvastatin's therapeutic index, which is relatively narrow when dose-dependent myopathy is considered
• The on-demand dosing pattern of bremelanotide, which limits but does not eliminate the interaction window

Because bremelanotide is injected subcutaneously on an as-needed basis (no more than once per 24 hours), the period of OATP inhibition is time-limited. Bremelanotide reaches peak plasma concentrations within approximately one hour post-dose and has a terminal half-life of roughly 2.7 hours [1]. By approximately 12 to 16 hours post-injection, plasma concentrations fall below levels likely to produce meaningful OATP inhibition in most patients.

Real-World Prescribing Implications

A 2021 analysis of FDA Adverse Event Reporting System (FAERS) data identified muscle-related adverse events as a recurring signal among patients on statin-OATP inhibitor combinations [5]. Bremelanotide-specific myopathy reports remain sparse given its niche indication, but the mechanistic basis for harm is well-established from analogous inhibitor pairs.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges that bremelanotide is one of two FDA-approved pharmacologic options for HSDD and notes the need for a careful medication review before prescribing [6]. Given that HSDD commonly affects perimenopausal and middle-aged women who are also candidates for statin therapy, the practical co-prescribing scenario is not unusual.

Pharmacokinetic Modeling: What Co-Administration Likely Does

No dedicated clinical pharmacokinetic study has examined the bremelanotide-rosuvastatin pair directly in human subjects, which is a recognized evidence gap. Mechanistic static models based on the inhibitory constants (Ki) reported in the bremelanotide new drug application (NDA) suggest that peak bremelanotide concentrations could increase rosuvastatin AUC by a factor of 1.5 to 3.0, depending on the dosing interval between the two drugs [1].

For context, the FDA rosuvastatin label warns that co-administration with cyclosporine (another OATP1B1/1B3 inhibitor) raised rosuvastatin Cmax by approximately 11-fold and AUC by approximately 7-fold in a dedicated crossover study [3]. Bremelanotide's inhibitory potency is lower than cyclosporine, so the magnitude of interaction should be smaller, but the directional risk remains the same.

Dose Timing as a Mitigation Tool

Given the short half-life of bremelanotide (2.7 hours) and its on-demand use, a practical mitigation strategy is to avoid taking rosuvastatin within 12 hours of bremelanotide administration. Patients who take rosuvastatin in the morning and use bremelanotide in the evening (or vice versa) may reduce co-peak plasma overlap. This is not a substitute for clinical judgment, and the FDA label does not endorse a specific separation interval.

Monitoring Recommendations

Laboratory Parameters

Clinicians who cannot avoid the combination should establish a baseline creatine kinase (CK) level before initiating bremelanotide. The American College of Cardiology/American Heart Association statin safety guideline recommends obtaining CK when symptoms of muscle injury appear rather than routinely, but the presence of a known OATP inhibitor shifts the calculus [7]. A pre-treatment CK level provides a reference point if symptoms develop.

If CK rises to more than 10 times the upper limit of normal in the setting of muscle symptoms, rosuvastatin should be stopped immediately, and the patient should be evaluated for rhabdomyolysis with a BMP to assess renal function [7].

Symptom Counseling

Patients should be told to report:

• Unexplained muscle pain, tenderness, or weakness
• Dark or cola-colored urine (myoglobinuria)
• Unusual fatigue disproportionate to activity level

These symptoms warrant prompt CK testing and clinical evaluation. The temporal relationship to bremelanotide dosing should be documented. Many patients do not connect a muscle symptom that appears 6 to 12 hours after an on-demand injection with the injection itself.

Alternative Management Strategies

Statin Selection

Not all statins carry equal OATP1B1/1B3 dependence. Fluvastatin is primarily a CYP2C9 substrate and has minimal reliance on OATP-mediated hepatic uptake [2]. For patients who need moderate LDL reduction and want to use bremelanotide, switching from rosuvastatin to fluvastatin may reduce the transporter-mediated interaction risk substantially, though this requires an assessment of cardiovascular risk goals and LDL targets.

Atorvastatin is an OATP1B1 substrate but also undergoes significant CYP3A4-mediated metabolism, which provides an alternative clearance route when OATP function is impaired [2]. Its net susceptibility to OATP inhibition is therefore lower than rosuvastatin's, though not negligible.

Lovastatin and simvastatin are primarily CYP3A4 substrates and not significant OATP1B1 substrates, but they carry their own myopathy risk through CYP3A4-mediated interactions and are generally disfavored for high-risk patients by current ACC/AHA guidelines [7].

Evaluating Continued Statin Need

Some patients taking rosuvastatin for primary prevention may have borderline risk profiles. Before adding bremelanotide, a prescriber should revisit the patient's 10-year ASCVD risk score (PCE) and ask whether statin intensity can be down-titrated or whether the patient's cardiovascular risk category truly mandates rosuvastatin specifically. This is not a reason to abandon statin therapy in high-risk patients; it is a reason to use the drug-drug interaction as an opportunity for a scheduled statin reassessment.

Patient Counseling Points

Practical conversation points for clinicians prescribing bremelanotide to a patient already on rosuvastatin:

1. Tell the patient directly that bremelanotide can raise the level of rosuvastatin in the bloodstream by slowing how the liver processes it.
2. Ask them to use bremelanotide as far from their rosuvastatin dose as their schedule permits. Most patients take rosuvastatin in the evening, which may conflict with the most common bremelanotide use timing.
3. Explain the specific muscle symptoms to watch for, and give them a concrete instruction: if they experience muscle pain or weakness within 24 hours of using bremelanotide, they should hold the rosuvastatin and call the clinic.
4. Document the counseling in the chart, including acknowledgment that the interaction was reviewed.
5. Consider a 6-week follow-up CK check if the patient intends to use bremelanotide more than once weekly.

The bremelanotide prescribing information specifies a maximum of one dose per 24 hours and no more than one dose expected per anticipated sexual activity event [1]. For most patients this means infrequent exposure, which reduces the cumulative interaction burden. A patient who uses bremelanotide twice monthly faces meaningfully lower aggregate risk than one using it weekly.

Summary of Evidence Gaps

The most significant limitation in counseling patients on this specific combination is the absence of a dedicated clinical DDI study. The FDA relied on in vitro transporter data and static mechanistic modeling to inform label language, a standard and accepted approach for transporter-mediated interactions at the NDA stage. However, it means clinicians cannot quote a precise rosuvastatin AUC fold-change figure from a controlled human study.

The University of Washington Drug Interaction Database and similar resources classify the interaction as "of concern" based on mechanistic grounds, consistent with FDA labeling [8]. Until a dedicated clinical PK study is published, prescribers should treat the FDA's "avoid" recommendation as the operational standard and document any deviation from it with clinical rationale.

Patients with the SLCO1B1 TT genotype (normal function) likely face a lower absolute risk than those with the CC variant, but genotyping is not yet standard practice outside of specialized lipid or pharmacogenomics clinics. The CPIC SLCO1B1/statin guideline is available to any clinician who wants to use genotype data if it is already in the patient's record [4].